299,244 Shares in Soleno Therapeutics, Inc. (NASDAQ:SLNO) Bought by Nationale Nederlanden Powszechne Towarzystwo Emerytalne S.A.

Nationale Nederlanden Powszechne Towarzystwo Emerytalne S.A. bought a new stake in shares of Soleno Therapeutics, Inc. (NASDAQ:SLNO - Free Report) in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund bought 299,244 shares of the company's stock, valued at approximately $13,451,000. Soleno Therapeutics comprises about 1.6% of Nationale Nederlanden Powszechne Towarzystwo Emerytalne S.A.'s investment portfolio, making the stock its 28th largest holding. Nationale Nederlanden Powszechne Towarzystwo Emerytalne S.A. owned about 0.69% of Soleno Therapeutics as of its most recent SEC filing.

Several other institutional investors have also recently added to or reduced their stakes in the business. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its position in Soleno Therapeutics by 24.8% during the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 27,504 shares of the company's stock worth $1,236,000 after acquiring an additional 5,462 shares during the period. Union Square Park Capital Management LLC acquired a new position in shares of Soleno Therapeutics during the fourth quarter valued at $2,248,000. Vestal Point Capital LP raised its stake in shares of Soleno Therapeutics by 47.2% during the fourth quarter. Vestal Point Capital LP now owns 1,060,000 shares of the company's stock valued at $47,647,000 after purchasing an additional 340,000 shares in the last quarter. Tang Capital Management LLC acquired a new stake in Soleno Therapeutics in the fourth quarter worth about $2,248,000. Finally, Tema Etfs LLC acquired a new stake in Soleno Therapeutics in the fourth quarter worth about $592,000. Institutional investors own 97.42% of the company's stock.

Soleno Therapeutics Stock Up 4.1%

NASDAQ:SLNO traded up $3.00 during trading hours on Friday, reaching $76.89. 474,984 shares of the company's stock were exchanged, compared to its average volume of 749,080. The company has a market capitalization of $3.87 billion, a P/E ratio of -23.16 and a beta of -2.67. Soleno Therapeutics, Inc. has a 12 month low of $36.93 and a 12 month high of $80.99. The business's 50-day simple moving average is $68.88 and its two-hundred day simple moving average is $55.71.

Soleno Therapeutics (NASDAQ:SLNO - Get Free Report) last released its quarterly earnings data on Wednesday, May 7th. The company reported ($0.95) earnings per share for the quarter, topping the consensus estimate of ($1.14) by $0.19. As a group, sell-side analysts anticipate that Soleno Therapeutics, Inc. will post -3.72 earnings per share for the current fiscal year.

Insider Activity

In other Soleno Therapeutics news, CEO Bhatnagar Anish sold 699,095 shares of the business's stock in a transaction on Thursday, March 27th. The shares were sold at an average price of $67.62, for a total transaction of $47,272,803.90. Following the sale, the chief executive officer now directly owns 577,076 shares of the company's stock, valued at $39,021,879.12. The trade was a 54.78% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Patricia C. Hirano sold 128,653 shares of the stock in a transaction on Thursday, March 27th. The shares were sold at an average price of $68.32, for a total value of $8,789,572.96. Following the completion of the sale, the insider now owns 55,789 shares of the company's stock, valued at $3,811,504.48. The trade was a 69.75% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 942,672 shares of company stock valued at $64,058,781 over the last three months. Insiders own 12.30% of the company's stock.

Analyst Upgrades and Downgrades

A number of research firms have commented on SLNO. Robert W. Baird boosted their price target on shares of Soleno Therapeutics from $102.00 to $105.00 and gave the stock an "outperform" rating in a research report on Thursday, May 8th. Laidlaw raised their price objective on shares of Soleno Therapeutics from $75.00 to $105.00 and gave the company a "buy" rating in a research note on Thursday, March 27th. Piper Sandler upped their target price on Soleno Therapeutics from $93.00 to $145.00 and gave the stock an "overweight" rating in a research report on Thursday, April 24th. Cantor Fitzgerald increased their price target on Soleno Therapeutics from $67.00 to $123.00 and gave the company an "overweight" rating in a research note on Thursday, March 27th. Finally, HC Wainwright reiterated a "buy" rating and set a $100.00 price target on shares of Soleno Therapeutics in a research report on Tuesday, April 15th. Eight investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, Soleno Therapeutics presently has a consensus rating of "Buy" and an average target price of $106.78.

Soleno Therapeutics Company Profile

Soleno Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet, which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome.